This is the authors' abstract. We don't add key points for this paper.
Study design systematic review and meta-analysis. Objective To evaluate the association between perioperative glucagon-like peptide-1 receptor agonists (GLP-1RAs) use and clinical outcomes after spine surgery. Methods PubMed, MEDLINE, Embase, Web of Science, and the Cochrane Library were searched through July 31, 2026. Comparative studies of adults undergoing spine surgery with versus without perioperative GLP-1RA exposure were pooled using random-effects models. Risk of bias was assessed with the Newcastle-Ottawa Scale and certainty with GRADE. Results Thirty-six retrospective cohorts involving 435,085 patients were included. GLP-1RA use was not associated with pseudarthrosis at 90 days (RR, 0.99; 95% CI, 0.25-3.98), but was associated with lower risk at 6 months (RR, 0.62; 95% CI, 0.56-0.68), 1 year (RR, 0.65; 95% CI, 0.61-0.69), 2 years (RR, 0.77; 95% CI, 0.66-0.89), and 3 years (RR, 0.80; 95% CI, 0.69-0.92). Revision risk was lower at 6 months and 2 years. GLP-1RA use was also associated with lower risks of selected systemic, infectious, and wound complications and reduced healthcare utilization, but with higher risks of hypoglycemia and adjacent segment disease. Conclusions In separate follow-up-specific analyses, GLP-1RA exposure was associated with lower pseudarthrosis and revision risks at selected intervals and with several other postoperative outcomes. These estimates do not establish a temporal drug effect or distinguish direct pharmacologic effects from weight loss, improved glycemic control, or confounding. Heterogeneity, possible overlapping cohorts, and very-low-certainty observational evidence preclude causal or treatment recommendations.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: